On March 16, 2023, QuiaPEG Pharmaceuticals Holding AB (publ) (the "Company") were given observation status with reference to material adverse uncertainty in respect of the Company's financial position. Today, November 8, 2023, the Company issued a press release with information that the Company has entered into a conditional agreement on a reverse takeover under which the Company inter alia will acquire IP rights from Rosemonkey Ltd, and Rosemonkey Ltd will receive new shares corresponding to 95 percent of the total number of shares in the Company as consideration. According to item 2.5.1 of the Nasdaq First North Growth Market Rulebook, the Exchange may for an issuer that undergoes substantial changes initiate a renewed review process of the issuer's fulfilment of applicable admission requirements. With reference to the above, the Exchange has decided that the Company shall undergo such a review process, after which the Exchange will decide whether to admit the Company's shares for continued trading on Nasdaq First North Growth Market. The rules of Nasdaq First North Growth Market also state that an issuer may be given observation status if it has been the subject of a reverse take-over or otherwise plans to make or has been subject to an extensive change in its business or organization so that the issuer upon an overall assessment appears to be an entirely new company. With reference to the above, Nasdaq Stockholm AB decides to update the observation status for the shares (QUIA, ISIN code SE0020678159, order book ID 200627), and the equity rights (QUIA TO9, ISIN code SE0019912817, order book ID 292737), in QuiaPEG Pharmaceuticals Holding AB (publ). For further information concerning this exchange notice please contact Enforcement & Investigations, telephone + 46 8 405 60 00. Nasdaq Stockholm AB
© 2023 GlobeNewswire
